MS clinical research studies across the US are actively enrolling participants. You may be eligible for an MS study if you:
Additional eligibility criteria apply for each study.
Click on a study to learn more about each MS study and see if you might qualify.
AGNOS is a clinical research study for patients recently diagnosed with relapsing-remitting multiple sclerosis (RRMS). If you qualify and choose to join the study, you will participate for about 18 months. If you agree to participate in the optional 12-month extension study, your participation will last for up to 30 months. Participants will receive the study drug (ofatumumab) by an autoinjector pen. Participants will receive an injection every 7 days for the first 2 weeks (day 1, 7, and 14) and once monthly starting at month 1 until month 18.
You may be eligible to participate if you:
Healthy volunteers will also be enrolled in the study so a friend or loved one can participate in the study with you as a study partner. Healthy volunteers will not receive treatment with the study drug.
The study will evaluate if treatment with ofatumumab early in a participant’s RRMS diagnosis improves and/or potentially changes the course of their disease.
Participants will help researchers learn important information about MS disease in patients recently diagnosed with RRMS that could be used in the future for diagnosis and management of RRMS. Your participation may help inform healthcare providers and enable them to make the best decisions for their patients.
There are 3 periods of the study: the screening period, the treatment period, and the optional extension period. The figure below shows what will happen during each period.
OLIKOS is a clinical research study evaluating the safety and effectiveness of a study drug (ofatumumab) after switching from treatment with Ocrevus (ocrelizumab) or Rituxan (rituximab) in patients with relapsing MS. The study drug is given by an autoinjector pen. Participants will receive an injection every 7 days for the first 2 weeks (day 1, 7, and 14) and once monthly starting at month 1. If you qualify and chose to participate, you will be asked to attend 5 appointments and 13 telephone calls with the study team for a maximum of 15 months.
You may be eligible to participate if you:
You can receive the study drug while staying in the comfort of your own home
Study drug is given at home as an injection under the skin so:
- No infusion room
- No intravenous catheter (IV)
There are 3 periods of the study: the screening period, the treatment period, and the follow-up period. The figure below shows what will happen during each period.
SOSTOS is a clinical research study that may find out if patients who have not had a relapse within the past 6 months might benefit from switching to ofatumumab (study drug) compared to continuing their current MS treatment. The study will also look at neurofilament light chain (NfL) which is a biomarker that may indicate a neurological decline. The study will look to see if patients with an elevated NfL may have a greater benefit from switching to study drug compared to staying on current treatment.
If you qualify and agree to join SOSTOS, you will be in the study for approximately 22 months and asked to come in for office visits about 12 times.
Some of the enrolled study patients will be randomly selected to wear a study watch to collect information on physical activity, sleep and vitals.
You may be eligible to participate if you:
Patients with RRMS could have ongoing nervous system damage despite no obvious signs or worsening symptoms. The study may help MS providers know when a patient may benefit from a therapy change to potentially help improve their long-term outcome and possibly prevent future disability. The study may give healthcare providers and patients new information to help make better therapy choices in the future.
There are 4 periods of the study: the screening period, the run-in period, the treatment period, and the follow-up period. The figure below shows what will happen during each period.
The Ofatumumab Flu Vaccine clinical research study is evaluating if participants receiving ofatumumab for multiple sclerosis (MS) can produce an adequate immune response to the influenza (flu) vaccine. Participants in this study will be assigned to 1 of 2 study groups:
Group 2: Participants who are currently taking prescribed ofatumumab
Group 3: Participants who are currently taking a prescribed interferon or glatiramer acetate
You may be eligible to participate if you:
OR
The study will evaluate the immune response to influenza vaccination in patients taking ofatumumab for MS. Treatment with ofatumumab can cause a reduction in B-cells, which are a type of white blood cell that makes antibodies. Your participation may help researchers understand the immune response to flu vaccination in patients taking ofatumumab.
There are 3 periods of the study: the screening period, the investigational period, and the optional extension period. The figure below shows what will happen during each period.
The Ofatumumab Covid-19 Vaccine study is evaluating if participants receiving ofatumumab for multiple sclerosis (MS) can produce an adequate immune response to the COVID-19 vaccines by Pfizer or Moderna. Participants in this study will be assigned to 1 of 6 study groups:
You may be eligible to participate if you:
The study will evaluate the immune response to COVID-19 vaccination in patients taking ofatumumab for MS. Treatment with ofatumumab can cause a reduction in B-cells, which are a type of white blood cell that makes antibodies. Your participation may help researchers understand the immune response to COVID-19 vaccination in patients taking ofatumumab.
There are 3 periods of the study: the screening period, the treatment period, and the follow-up period. The figure below shows what will happen during each period.
All trademarks are the property of their respective owners.
